Abstract
Strategies for the development of novel tuberculosis chemotherapeutics against existing drug resistant strains involve the identification and inhibition of novel drug targets as well as the design and synthesis of compounds against historical targets. InhA, the enoyl reductase from the mycobacterial type II fatty acid biosynthesis pathway, is a target of the frontline chemotherapeutic, isoniazid (INH). Importantly, the majority of INH-resistant clinical isolates arise from mutations in KatG, the enzyme responsible for activating isoniazid, into its active form. Thus compounds that inhibit InhA without first requiring KatG activation will be active against the majority of INH resistant strains of Mycobacterium tuberculosis. This review describes the role of InhA in cell wall biosynthesis and recent progress in the development of novel diphenyl ether-based InhA inhibitors that have activity against both sensitive and drug resistant strains of M. tuberculosis.
Keywords: InhA, enoyl reductase, fatty acid biosynthesis, mycolic acid, cell wall, mycobacterium, isoniazid, diphenyl ether, triclosan
Current Topics in Medicinal Chemistry
Title: Development of Modern InhA Inhibitors to Combat Drug Resistant Strains of Mycobacterium tuberculosis
Volume: 7 Issue: 5
Author(s): Peter J. Tonge, Caroline Kisker and Richard A. Slayden
Affiliation:
Keywords: InhA, enoyl reductase, fatty acid biosynthesis, mycolic acid, cell wall, mycobacterium, isoniazid, diphenyl ether, triclosan
Abstract: Strategies for the development of novel tuberculosis chemotherapeutics against existing drug resistant strains involve the identification and inhibition of novel drug targets as well as the design and synthesis of compounds against historical targets. InhA, the enoyl reductase from the mycobacterial type II fatty acid biosynthesis pathway, is a target of the frontline chemotherapeutic, isoniazid (INH). Importantly, the majority of INH-resistant clinical isolates arise from mutations in KatG, the enzyme responsible for activating isoniazid, into its active form. Thus compounds that inhibit InhA without first requiring KatG activation will be active against the majority of INH resistant strains of Mycobacterium tuberculosis. This review describes the role of InhA in cell wall biosynthesis and recent progress in the development of novel diphenyl ether-based InhA inhibitors that have activity against both sensitive and drug resistant strains of M. tuberculosis.
Export Options
About this article
Cite this article as:
Tonge J. Peter, Kisker Caroline and Slayden A. Richard, Development of Modern InhA Inhibitors to Combat Drug Resistant Strains of Mycobacterium tuberculosis, Current Topics in Medicinal Chemistry 2007; 7 (5) . https://dx.doi.org/10.2174/156802607780059781
DOI https://dx.doi.org/10.2174/156802607780059781 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Inhibition of 5-enolpyruvylshikimate-3-phosphate Synthase as a Model for Development of Novel Antimicrobials
Current Drug Targets Stopping of the Downtrend of Tuberculosis in Iran, a Systematic Review of Associated Risk Factors
Infectious Disorders - Drug Targets Multivariate Calibration: A Powerful Tool in Pharmaceutical Analysis
Current Pharmaceutical Analysis NOS: Molecular Mechanisms, Clinical Aspects, Therapeutic and Monitoring Approaches
Current Drug Targets - Inflammation & Allergy Genotypic Characterization of Vancomycin-Resistant Enterococcus spp. In Tertiary Center, Iran
Infectious Disorders - Drug Targets Glutamate and Schizophrenia
Current Neuropharmacology Efflux Pump and its Inhibitors: Novel Targets to Combat Drug Resistance
Anti-Infective Agents Electroporation Advances in Large Animals
Current Gene Therapy Oxidative Stress in the Cochlea: An Update
Current Medicinal Chemistry In Vitro, In Silico and Ex Vivo Studies of Dihydroartemisinin Derivatives as Antitubercular Agents
Current Topics in Medicinal Chemistry P2X Receptors and Inflammation
Current Medicinal Chemistry Pharmaceutical Care: Past, Present and Future
Current Pharmaceutical Design Pyridines and Imidazopyridines with Medicinal Significance
Current Topics in Medicinal Chemistry Biofunctionalized Nano-antimicrobials - Progress, Prospects and Challenges
Current Topics in Medicinal Chemistry Phenothiazine: A Better Scaffold against Tuberculosis
Mini-Reviews in Medicinal Chemistry Sulphur-Containing Heterocycles as Antimycobacterial Agents: Recent Advances in Thiophene and Thiadiazole Derivatives
Current Topics in Medicinal Chemistry A Review on Extraction, Synthesis and Anticancer Activity of Betulinic Acid
Current Bioactive Compounds Dual-acting of Hybrid Compounds - A New Dawn in the Discovery of Multi-target Drugs: Lead Generation Approaches
Current Topics in Medicinal Chemistry Perspectives on the Development of Novel Potentially Active Quinolones Against Tuberculosis and Cancer
Mini-Reviews in Medicinal Chemistry Probiotics/Prebiotics in Viral Respiratory Infections: Implication for Emerging Pathogens
Recent Patents on Biotechnology